Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
PFTs
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?
Related Questions
How do you mitigate the risk of inadverdent under or over diagnosis of COPD in certain populations with transition to race-neutral spirometry reference equations?
What are the potential challenges and benefits of implementing z score thresholds in clinical practice for COPD severity classification, and how might this affect patient outcomes?
How might the introduction of brensocatib as a treatment option impact the use of other anti- inflammatory or antibiotic therapies currently employed in bronchiectasis management?
Should thunderstorm asthma be incorporated into asthma action plans?
Do you recommend that your patients with COPD avoid gabapentin or pregabalin entirely, given the increased rate of exacerbations noted in patients on these medications?
How do you choose roflumilast vs ensifentrine in COPD patients with dyspnea despite adequate LABA + LAMA (+ ICS therapy where indicated)?
What role might depemokimab play in the stepwise approach to asthma management, especially for patients who have previously failed other biologic therapies?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
What is your approach to addressing comorbidities that influence asthma severity?
